This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center
ClinicalTrials.gov Identifier:
NCT00609791
First received: February 6, 2008
Last updated: March 1, 2017
Last verified: March 2017
February 6, 2008
March 1, 2017
January 25, 2008
August 25, 2017   (Final data collection date for primary outcome measure)
  • Age-related changes in the pharmacokinetics (pK) [ Time Frame: Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours ]
  • Age-related changes in the pharmacodynamics (toxicity) [ Time Frame: Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours ]
  • Age-related changes in the pharmacokinetics (pK)
  • Age-related changes in the pharmacodynamics (toxicity)
Complete list of historical versions of study NCT00609791 on ClinicalTrials.gov Archive Site
  • Response [ Time Frame: Assessed after every 2 cycles of therapy until progression ]
  • Time to progression [ Time Frame: 1 year after completion of treatment ]
  • Predictors of pK parameters [ Time Frame: After week 1 of treatment ]
  • Predictors of the need for dose reduction, dose delays, or grade 3 or 4 toxicity [ Time Frame: At the completion of treatment ]
  • Response
  • Time to progression
  • Predictors of pK parameters
  • Predictors of the need for dose reduction, dose delays, or grade 3 or 4 toxicity
Not Provided
Not Provided
 
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics

RATIONALE: Gathering information from patients of different ages receiving paclitaxel albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors understand how the age of the patient changes the way the drug works.

PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients of different ages with metastatic breast cancer.

OBJECTIVES:

Primary

  • To determine age-related changes in the pharmacokinetics (pK) of weekly paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in patients with metastatic breast cancer.
  • To determine age-related changes in the pharmacodynamics (toxicity) of nab-paclitaxel in these patients.

Secondary

  • To determine response and time to progression in these patients.
  • To explore predictors of pK parameters in these patients.
  • To explore predictors of the need for dose reduction, dose delays, or grade 3 or 4 toxicity in these patients.

OUTLINE: Patients are stratified by age in years (< 50 vs 50-60 vs 60-70 vs > 70).

Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once daily on days 1, 8, and 15 as planned. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Blood is drawn for pharmacokinetic studies periodically during course 1.

Patients complete questionnaires regarding risk factors that would predict for pharmacokinetic parameters at baseline, prior to the third course of treatment, and at end of study. Data collected include medical characteristics, demographics, functional status, comorbidity, psychological status, social functioning and support, nutritional status, and cognition.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Breast Cancer
  • Drug: paclitaxel albumin-stabilized nanoparticle formulation
    100 mg/m2 3 weeks on 1 week off
  • Other: pharmacological study
    Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
  • Other: physiologic testing
    Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
  • Other: questionnaire administration
    Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
  • Other: study of socioeconomic and demographic variables
    Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
  • Procedure: cognitive assessment
    Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
  • Procedure: psychosocial assessment and care
    Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Experimental: nab-paclitaxel
Interventions:
  • Drug: paclitaxel albumin-stabilized nanoparticle formulation
  • Other: pharmacological study
  • Other: physiologic testing
  • Other: questionnaire administration
  • Other: study of socioeconomic and demographic variables
  • Procedure: cognitive assessment
  • Procedure: psychosocial assessment and care
Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, Katheria V, Rotter AJ, Wong C, Choi A, Feng T, Ramani R, Doan CM, Brown J, Somlo G. Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist. 2015 Jan;20(1):37-44. doi: 10.1634/theoncologist.2014-0202. Epub 2014 Dec 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
August 25, 2017
August 25, 2017   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Diagnosis of metastatic breast cancer
  • Any estrogen receptor, progesterone receptor, or HER-2/neu status allowed as long as the patient will receive paclitaxel albumin-stabilized nanoparticle formulation alone
  • First- or second-line chemotherapy treatment for metastatic disease planned

Exclusion criteria:

  • Untreated CNS metastases or symptomatic CNS metastases requiring escalating doses of corticosteroids

PATIENT CHARACTERISTICS:

  • Karnofsky performance status 70-100%
  • WBC ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 9.0 g/dL
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastases are present in the absence of liver metastases)
  • Bilirubin ≤ 1.5 mg/dL
  • Peripheral neuropathy ≤ grade 1
  • Creatinine clearance ≥ 30 mL/min (calculated or 24-hour)
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Not pregnant or nursing
  • No known history of allergic reactions to paclitaxel
  • No serious or uncontrolled infection
  • Ability to understand and the willingness to sign a written informed consent document

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No ≥ grade 2 toxicity from prior therapy (other than alopecia)
  • No taxane for adjuvant therapy or metastatic disease within the past 12 months
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00609791
07157
P30CA033572 ( US NIH Grant/Contract Award Number )
CHNMC-07157
ABRAXIS-ABX206-BC07US
CDR0000586461 ( Registry Identifier: NCI PDQ )
Yes
Not Provided
Not Provided
Not Provided
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
Principal Investigator: Arti Hurria, MD City of Hope Comprehensive Cancer Center
City of Hope Medical Center
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP